Phase 2 Completed N=80 Randomized Double-blind Treatment

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

Platysmal Bands

Source: ClinicalTrials.gov NCT04080882 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2021

Primary outcomePrimary: Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo — 3; 36 Participants

Summary

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

Outcome Measures

Outcome	Result	p-value
PRIMARY Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo	3; 36	—

Eligibility Criteria

Inclusion Criteria

Moderate to severe platysmal bands at maximum contraction as assessed by the Investigator using a photographic scale
Platysmal bands graded as Level 3 or 4 at maximum contraction as assessed by the subject using a photographic scale

Exclusion Criteria

Botulinum toxin treatment of any serotype below the lower orbital rim, in the neck or chest within 12 months prior to study treatment

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04080882). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.